Learn how Siemens’ FAST CARE Technology speeds up time-consuming CT procedures and simultaneously reduces dosage.
FAST CARE Technology
To give medical professionals more time to take better care of their patients, our new FAST CARE Technology accelerates workflow and lowers radiation exposure to previously unseen levels – to help you leverage untapped potentials in patient-centric productivity.
Be FAST
FAST – our Fully Assisting Scanner Technologies – make time-consuming and complex procedures faster as well as far more intuitive. Your scans will also be more reproducible and less prone to errors.
Take CARE
CARE – our Combined Applications to Reduce Exposure – provide you with excellent image quality at the right dose level..
FAST CARE Technology offers comprehensive software packages adjusted to your needs and clinical fields. In combination with syngo.via, the FAST CARE Technology helps to make the entire examination even more streamlined, helping to enable a highly-reliable diagnosis with less patient burden – from scan preparation to data evaluation.
More information about the FAST CARE Technology can be found here
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.